You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort

Article info

Article menu

Download PDFPDF

Rheumatoid arthritis
Original research
Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort

Authors

  • Joanna Kedra Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), UMR S 1136, Sorbonne Université, Paris, FranceAPHP, Rheumatology Department, Hopital Universitaire Pitie Salpetriere, Paris, France PubMed articlesGoogle scholar articles
  • Alexandre Lafourcade Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), UMR S 1136, Sorbonne Université, Paris, France PubMed articlesGoogle scholar articles
  • Bernard Combe Rheumatology, CHU Montpellier, Montpellier, France PubMed articlesGoogle scholar articles
  • Maxime Dougados Hopital Cochin (AP-HP), Rheumatology, Université de Paris, Paris, France PubMed articlesGoogle scholar articles
  • David Hajage Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), UMR S 1136, Sorbonne Université, Paris, FranceCentre de Pharmacoépidémiologie (Cephepi), APHP Pitié-Salpêtrière Hospital, Paris, France PubMed articlesGoogle scholar articles
  • Bruno Fautrel Institut Pierre Louis d'Epidémiologie et de Santé Publique (IPLESP), UMR S 1136, Sorbonne Université, Paris, FranceAPHP, Rheumatology Department, Hopital Universitaire Pitie Salpetriere, Paris, France PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Joanna Kedra; jkedra.pro{at}gmail.com
View Full Text

Citation

Kedra J, Lafourcade A, Combe B, et al
Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort
RMD Open 2022;8:e002040. doi: 10.1136/rmdopen-2021-002040

Publication history

  • Received October 18, 2021
  • Accepted February 22, 2022
  • First published May 9, 2022.
Online issue publication 
June 08, 2023

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.